Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 4, Pages 90
Publisher
MDPI AG
Online
2018-03-23
DOI
10.3390/cancers10040090
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Hippo pathway as a drug target in gastric cancer
- (2018) Yiting Qiao et al. CANCER LETTERS
- Progress in the Management of Malignant Pleural Mesothelioma in 2017
- (2018) Amanda J. McCambridge et al. Journal of Thoracic Oncology
- Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma
- (2018) Anne S. Tsao et al. Journal of Thoracic Oncology
- Targeting YAP in malignant pleural mesothelioma
- (2017) Wen-Qian Zhang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis
- (2017) David B. Nelson et al. JOURNAL OF CLINICAL ONCOLOGY
- Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
- (2017) Federica Grosso et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidemiology of Environmental Exposure and Malignant Mesothelioma
- (2017) Bian Liu et al. Journal of Thoracic Oncology
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- Radiotherapy for the treatment of malignant pleural mesothelioma
- (2017) Marc de Perrot et al. LANCET ONCOLOGY
- Targeting BAP1: a new paradigm for mesothelioma
- (2017) L.M. Schunselaar et al. LUNG CANCER
- Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry
- (2017) Tomoyuki Hida et al. LUNG CANCER
- Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
- (2017) Jonathan Cooper et al. MOLECULAR CANCER THERAPEUTICS
- E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells
- (2017) T Kato et al. ONCOGENE
- Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration
- (2017) Li Jia et al. PROSTATE
- VGLL4 targets a TCF4–TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer
- (2017) Shi Jiao et al. Nature Communications
- Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
- (2017) Sabrina Lagniau et al. Oncotarget
- Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer
- (2017) Sho Nambara et al. Oncotarget
- Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma
- (2017) Peter W. Szlosarek et al. JAMA Oncology
- Verteporfin inhibits growth of human glioma in vitro without light activation
- (2017) Ahmad Al-Moujahed et al. Scientific Reports
- A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma
- (2016) Sumanta K. Pal et al. CANCER
- G protein-coupled receptors as promising cancer targets
- (2016) Ying Liu et al. CANCER LETTERS
- Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation
- (2016) Tatsuo Kakiuchi et al. CARCINOGENESIS
- HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
- (2016) A. Napolitano et al. CLINICAL CANCER RESEARCH
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2 , in Malignant Pleural Mesothelioma
- (2016) Robin Tranchant et al. CLINICAL CANCER RESEARCH
- Mesothelial cells and peritoneal homeostasis
- (2016) Steven Eugene Mutsaers et al. FERTILITY AND STERILITY
- Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
- (2016) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study
- (2016) Hongjiang Wu et al. LUNG CANCER
- AJUBA LIM Proteins Limit Hippo Activity in Proliferating Cells by Sequestering the Hippo Core Kinase Complex in the Cytosol
- (2016) Radhika Jagannathan et al. MOLECULAR AND CELLULAR BIOLOGY
- Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma
- (2016) Mayura Meerang et al. Molecular Oncology
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways
- (2016) Giulia Santinon et al. TRENDS IN CELL BIOLOGY
- A splicing isoform of TEAD4 attenuates the Hippo–YAP signalling to inhibit tumour proliferation
- (2016) Yangfan Qi et al. Nature Communications
- Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
- (2016) Valentina Monica et al. Oncotarget
- The Hippo signaling pathway provides novel anti-cancer drug targets
- (2016) June Sung Bae et al. Oncotarget
- Merlin/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent
- (2016) Hiroki Hikasa et al. Cell Reports
- Searching for targets for the systemic therapy of mesothelioma
- (2015) R. A. Stahel et al. ANNALS OF ONCOLOGY
- Metformin in Cancer Treatment and Prevention
- (2015) Daniel R. Morales et al. Annual Review of Medicine
- Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
- (2015) Fa-Xing Yu et al. CELL
- Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway
- (2015) Youjun Li et al. CELL RESEARCH
- Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides
- (2015) Zheng Zhou et al. FASEB JOURNAL
- Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing
- (2015) Akihiko Miyanaga et al. Journal of Thoracic Oncology
- SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
- (2015) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
- (2015) Lee M Krug et al. LANCET ONCOLOGY
- The prognostic significance of BAP1, NF2 and CDKN2A in malignant peritoneal mesothelioma
- (2015) Aatur D Singhi et al. MODERN PATHOLOGY
- Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway
- (2015) Jung-Soon Mo et al. NATURE CELL BIOLOGY
- AMPK modulates Hippo pathway activity to regulate energy homeostasis
- (2015) Wenqi Wang et al. NATURE CELL BIOLOGY
- Loss of BAP1 function leads to EZH2-dependent transformation
- (2015) Lindsay M LaFave et al. NATURE MEDICINE
- Role of Merlin/NF2 inactivation in tumor biology
- (2015) A M Petrilli et al. ONCOGENE
- Merlin Isoforms 1 and 2 Both Act as Tumour Suppressors and Are Required for Optimal Sperm Maturation
- (2015) Ansgar Zoch et al. PLoS One
- Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis inMob1a/1b-deficient mice
- (2015) Miki Nishio et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Current surgical strategies for malignant pleural mesothelioma
- (2015) Teruhisa Takuwa et al. SURGERY TODAY
- Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer
- (2015) Kim Moran-Jones et al. Oncotarget
- Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
- (2015) Peter Johansson et al. Oncotarget
- Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers
- (2015) Yusuke Oku et al. FEBS Open Bio
- YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes.
- (2015) Erica Lorenzetto et al. Oncotarget
- Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
- (2014) Fa-Xing Yu et al. CANCER CELL
- Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry
- (2014) Xiaodong Feng et al. CANCER CELL
- Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus
- (2014) Wei Li et al. CANCER CELL
- A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer
- (2014) Shi Jiao et al. CANCER CELL
- VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex
- (2014) Wenjing Zhang et al. CELL RESEARCH
- The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease
- (2014) X. Varelas DEVELOPMENT
- Molecular insights into NF2 /Merlin tumor suppressor function
- (2014) Jonathan Cooper et al. FEBS LETTERS
- Deregulated expression of connective tissue growth factor (CTGF/CCN2)is linked to poor outcome in human cancer
- (2014) Julia E. Wells et al. INTERNATIONAL JOURNAL OF CANCER
- Connective tissue growth factor andβ-catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma
- (2014) Li Jiang et al. JOURNAL OF PATHOLOGY
- Identification, Mechanism of Action, and Antitumor Activity of a Small Molecule Inhibitor of Hippo, TGF- , and Wnt Signaling Pathways
- (2014) D. Basu et al. MOLECULAR CANCER THERAPEUTICS
- Metabolic control of YAP and TAZ by the mevalonate pathway
- (2014) Giovanni Sorrentino et al. NATURE CELL BIOLOGY
- Statins Do Not Alter the Incidence of Mesothelioma in Asbestos Exposed Mice or Humans
- (2014) Cleo Robinson et al. PLoS One
- Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
- (2014) I. M. Shapiro et al. Science Translational Medicine
- Energy Stress Regulates Hippo-YAP Signaling Involving AMPK-Mediated Regulation of Angiomotin-like 1 Protein
- (2014) Michael DeRan et al. Cell Reports
- Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells
- (2013) Simon A. Fox et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Molecular pathogenesis of malignant mesothelioma
- (2013) Y. Sekido CARCINOGENESIS
- Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
- (2013) Sophie Papa et al. Journal of Thoracic Oncology
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
- (2013) Randy Johnson et al. NATURE REVIEWS DRUG DISCOVERY
- LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade
- (2013) I Tanaka et al. ONCOGENE
- CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
- (2013) A. Neesse et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility
- (2013) Z. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
- (2013) V. E. Clark et al. SCIENCE
- Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma
- (2012) Yoshie Yoshikawa et al. CANCER SCIENCE
- Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling
- (2012) Fa-Xing Yu et al. CELL
- Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP
- (2012) Y. Liu-Chittenden et al. GENES & DEVELOPMENT
- Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis
- (2012) B. Zhao et al. GENES & DEVELOPMENT
- TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth
- (2012) Makiko Fujii et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report
- (2012) Arkadiusz Z. Dudek et al. Journal of Thoracic Oncology
- Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
- (2012) Valerie W. Rusch et al. Journal of Thoracic Oncology
- Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium
- (2012) Nicholas P. Campbell et al. LUNG CANCER
- YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes
- (2012) T Mizuno et al. ONCOGENE
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Review on clinical trials of targeted treatments in malignant mesothelioma
- (2011) Jan Nyrop Jakobsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- LATS2 Is a Tumor Suppressor Gene of Malignant Mesothelioma
- (2011) H. Murakami et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
- (2011) Scott A. Laurie et al. Journal of Thoracic Oncology
- The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
- (2011) Matthew Bott et al. NATURE GENETICS
- Germline BAP1 mutations predispose to malignant mesothelioma
- (2011) Joseph R Testa et al. NATURE GENETICS
- Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus
- (2010) Wei Li et al. CELL
- The Hippo Signaling Pathway in Development and Cancer
- (2010) Duojia Pan DEVELOPMENTAL CELL
- Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
- (2010) J. W. Harbour et al. SCIENCE
- CDKN2A,NF2, andJUNare dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis
- (2009) Mohamed Guled et al. GENES CHROMOSOMES & CANCER
- Malignant Pleural Mesothelioma
- (2009) Anne S. Tsao et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
- (2009) M. A. Lopez-Lago et al. MOLECULAR AND CELLULAR BIOLOGY
- A Conditional Mouse Model for Malignant Mesothelioma
- (2008) Johan Jongsma et al. CANCER CELL
- Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1and LPA2
- (2008) Tadaaki Yamada et al. CANCER SCIENCE
- YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation
- (2008) Toshihiko Yokoyama et al. CARCINOGENESIS
- Functional inactivation of NF2/merlin in human mesothelioma
- (2008) Claudio Thurneysen et al. LUNG CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now